Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)
China · Delayed Price · Currency is CNY 42.37
-2.80 (-6.20%)
Oct 23, 2026, 11:29 AM CST
Xiamen Amoytop Biotech Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 884.74 | 553.16 | 371.82 | 412.96 | 301.24 | 285.42 |
Trading Asset Securities | 1,356 | 462.48 | 289.96 | 257.08 | 270.78 | 196.38 |
Cash & Short-Term Investments | 2,241 | 1,016 | 661.79 | 670.04 | 572.02 | 481.8 |
Cash Growth | 171.42% | 53.47% | -1.23% | 17.14% | 18.73% | 3.53% |
Accounts Receivable | 1,362 | 1,244 | 808.52 | 441.02 | 223.05 | 206.28 |
Other Receivables | 71.9 | 22.22 | 22.34 | 17.87 | 20.17 | 21.67 |
Receivables | 1,434 | 1,266 | 830.86 | 458.9 | 243.22 | 227.94 |
Inventory | 431.06 | 414.9 | 263.55 | 187.02 | 129.73 | 116.49 |
Other Current Assets | 88.74 | 33.87 | 70.9 | 24.24 | 10.64 | 8.19 |
Total Current Assets | 4,194 | 2,730 | 1,827 | 1,340 | 955.61 | 834.42 |
Property, Plant & Equipment | 1,073 | 966.6 | 686.76 | 490.85 | 389.77 | 192.92 |
Goodwill | 64.48 | 64.48 | - | - | - | - |
Other Intangible Assets | 314.67 | 359.23 | 170.85 | 191.54 | 121.69 | 146.91 |
Long-Term Deferred Tax Assets | 126.27 | 97.53 | 69.09 | 43.66 | 47.18 | 34.96 |
Long-Term Deferred Charges | 82.05 | 63.39 | 221.2 | 176.7 | 229.25 | 169.14 |
Other Long-Term Assets | 48.34 | 91.91 | 75.43 | 112.98 | 26.05 | 44.99 |
Total Assets | 6,065 | 4,374 | 3,050 | 2,356 | 1,770 | 1,424 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 130.07 | 97.38 | 57.76 | 39.73 | 50.91 | 8.14 |
Accrued Expenses | 135.01 | 288.37 | 233.75 | 244.46 | 159.55 | 120.4 |
Short-Term Debt | 39.78 | 30.65 | - | - | - | 10 |
Current Portion of Long-Term Debt | 17.73 | 6.09 | - | - | - | - |
Current Portion of Leases | - | 10.74 | 5.67 | 4.16 | 4.18 | 5.79 |
Current Income Taxes Payable | 75.8 | 91.28 | 50.27 | 48.95 | 41.97 | 24.42 |
Current Unearned Revenue | 52.12 | 55.9 | 63.13 | 60.05 | 7.23 | 5.18 |
Other Current Liabilities | 120.35 | 126.71 | 10.06 | 6.31 | 4.05 | 3.3 |
Total Current Liabilities | 570.88 | 707.11 | 420.63 | 403.66 | 267.89 | 177.23 |
Long-Term Debt | 2,115 | 104 | - | - | - | - |
Long-Term Leases | 26.93 | 24.49 | 3.27 | 3.76 | 5.56 | 9.37 |
Long-Term Unearned Revenue | 66.38 | 36.51 | 32.96 | 40.62 | 47.68 | 51.25 |
Long-Term Deferred Tax Liabilities | 6.03 | 7.7 | 0.93 | 0.41 | 15.15 | 5.54 |
Other Long-Term Liabilities | 44.67 | 44.13 | 39.31 | 31.25 | 25.99 | 19.53 |
Total Liabilities | 2,830 | 923.94 | 497.1 | 479.69 | 362.27 | 262.91 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 408.19 | 408.19 | 406.8 | 406.8 | 406.8 | 406.8 |
Additional Paid-In Capital | 574.52 | 528.99 | 413.14 | 397.04 | 397.04 | 397.04 |
Retained Earnings | 2,739 | 2,512 | 1,733 | 1,073 | 603.76 | 357.42 |
Shareholders' Equity | 3,235 | 3,450 | 2,553 | 1,876 | 1,408 | 1,161 |
Total Liabilities & Equity | 6,065 | 4,374 | 3,050 | 2,356 | 1,770 | 1,424 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 2,199 | 175.97 | 8.94 | 7.92 | 9.74 | 25.16 |
Net Cash (Debt) | 41.51 | 839.67 | 652.85 | 662.11 | 562.28 | 456.63 |
Net Cash Growth | -93.94% | 28.62% | -1.40% | 17.76% | 23.14% | 2.28% |
Net Cash Per Share | 0.10 | 2.05 | 1.60 | 1.63 | 1.39 | 1.13 |
Filing Date Shares Outstanding | 399.06 | 408.19 | 406.8 | 406.8 | 406.8 | 406.8 |
Total Common Shares Outstanding | 399.06 | 408.19 | 406.8 | 406.8 | 406.8 | 406.8 |
Working Capital | 3,623 | 2,023 | 1,406 | 936.53 | 687.72 | 657.19 |
Book Value Per Share | 8.11 | 8.45 | 6.28 | 4.61 | 3.46 | 2.85 |
Tangible Book Value | 2,856 | 3,026 | 2,382 | 1,685 | 1,286 | 1,014 |
Tangible Book Value Per Share | 7.16 | 7.41 | 5.86 | 4.14 | 3.16 | 2.49 |
Buildings | - | 491.9 | 291.61 | 135.53 | 118.65 | 21.31 |
Machinery | - | 591.85 | 392.63 | 319.97 | 271.83 | 177.83 |
Construction In Progress | - | 99.71 | 181.56 | 183.72 | 135.81 | 118 |